Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the United States1 and is responsible for approximately 700,000 hospitalizations each year.2 COPD-related costs in the United States exceed $50 billion per year and are expected to increase.3 The increasing costs associated with COPD management are a substantial burden on the health care system. To help manage this burden, current guidelines recommend the use of several long-acting inhaled medications for the treatment of COPD.4 In this white paper, learn about current guidelines for management of COPD and available dosage forms of long-acting inhaled medications, and recognize opportunities that may reduce medication waste through appropriate use of available COPD treatments. This supplement was developed by Pharmacy Times® with support from Sunovion Pharmaceuticals Inc. SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2017 Sunovion Pharmaceuticals Inc. All rights reserved. 10/17 LEG-BRO021-17 To access this publication, Long-acting Medication Use in COPD: Opportunities for Minimizing Medication Waste in the Hospital Setting, please click here or on the button below. References Hoyert DL, Xu J; Centers for Disease Control and Prevention. Deaths: preliminary data for 2011. National Vital Statistics Reports. 2012;61(6):1-52. www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf. Accessed June 26, 2017. Krishnan JA, Gussin HA, Prieto-Centurion V, Sullivan JL, Zaidi F, Thomashow BM. Integrating COPD into patient-centered hospital readmissions reduction programs. Chronic Obstr Pulm Dis. 2015;2(1):70-80. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-245. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017:1-123.